IP Library Patent Application 15188640
Patent Application
App. No. 15/188,640

COMPOSITIONS AND METHODS FOR DETECTING CANCER METASTASIS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/188,640
Abstract

The present invention encompasses compositions and methods for detecting cancer metastasis.

Claims (21)

1 . A method for determining the risk of melanoma metastasis in a subject, the method comprising:

(a) analyzing BAP1 nucleic acid from a cell in a sample obtained from a subject,

(b) detecting the presence of a truncating in the BAP1 nucleic acid mutation using multiplex ligation-dependent probe amplification, wherein the mutation is selected from the group consisting of:

i. a nonsense mutation selected from the group consisting of Q36X, W196X and Q253X of BAP1;

ii. an insertion or deletion mutation in exon 2, 4, 5, 6, 7, 8, 9, 11, 12, 13 or 17 of BAP1; and

iii. a splice acceptor mutation in exon 16 of BAP1; and

(c) identifying the subject as having an increased risk for metastasis when a mutation is detected.

2 . The method of claim 1 , wherein the melanoma is uveal melanoma.

3 . The method of claim 1 , wherein the sample is a tumor sample.

4 . The method of claim 3 , wherein the sample is collected from a primary tumor or from a circulating tumor cell.

5 . The method of claim 4 , wherein the circulating tumor cell is collected from a bodily fluid.

6 . A method for prognosing melanoma in a subject, the method comprising:

(a) analyzing BAP1 nucleic acid from a cell in a sample obtained from a subject,

(b) detecting the presence of a truncating mutation in the BAP1 nucleic acid mutation using multiplex ligation-dependent probe amplification, wherein the mutation is selected from the group consisting of:

i. a nonsense mutation selected from the group consisting of Q36X, W196X and Q253X of BAP1; and

ii. an insertion or deletion mutation in exon 2, 4, 5, 6, 7, 8 or 9 of BAP1; and

(c) identifying the subject as having poor prognosis when a mutation is detected.

7 . The method of claim 6 , wherein the melanoma is uveal melanoma.

8 . The method of claim 6 , wherein the sample is a tumor sample.

9 . The method of claim 8 , wherein the sample is collected from a primary tumor or from a circulating tumor cell.

10 . The method of claim 9 , wherein the circulating tumor cell is collected from a bodily fluid.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 19, 2018
From: WASHINGTON UNIVERSITY IN ST. LOUIS
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 047812/0501 →
CONFIRMATORY LICENSE Recorded Dec 18, 2018
From: WASHINGTON UNIVERSITY IN ST. LOUIS
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 047949/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2017
From: BOWCOCK, ANNE M.; HARBOUR, JAMES WILLIAM
To: WASHINGTON UNIVERSITY
Reel/Frame 043900/0728 →